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The degeneration of articular cartilage represents an ongoing challenge at the clinical and basic level. Tissue engineering and
regenerative medicine using stem/progenitor cells have emerged as valid alternatives to classical reparative techniques. This
review oﬀers a brief introduction and overview of the ﬁeld, highlighting a number of tissue sources for stem/progenitor cell
populations. Emphasis is given to recent developments in both clinical and basic sciences. The relative strengths and weaknesses
of each tissue type are discussed.
1. Introduction
Articular cartilage has a poor self-healing potential, mainly
due to the lack of vascularisation and the paucity of undiﬀer-
entiated cells [1]. Thus, if focal cartilage lesions are left
untreated, they can progress to more extensive defects and
may ultimately require treatment with joint replacement sur-
gery if conservative options fail. The aim of this review is to
describe in detail recent ﬁndings in both basic and clinical
studies that have adapted cells from a variety of cell sources
to cartilage repair strategies.
Current treatments for cartilage repair are mainly
focused on bone marrow stimulation techniques: such as
abrasive chondroplasty, subchondral drilling, microfracture
and, more recently, nanofractures [2]. The aim of these
techniques is to allow migration to the damaged area and
the subsequent chondrogenic diﬀerentiation of multipotent
bone marrow-derived stromal/stem cells (BMSCs). However,
often, the regenerated tissue does not possess the same bio-
chemical and biomechanical properties of the native carti-
lage; therefore, it is not able to resist the continuous stresses
placed upon it, and it quickly degenerates [3]. Hence, new
treatment options for articular cartilage lesions have grown
in recent decades, due to promising results obtained with
the development of new therapeutic options.
Tissue engineering strategies aim to regenerate the dam-
aged tissue and restore a biologically and biomechanically
valid articular surface. This requires three components,
which may be alternately combined. The ﬁrst is a suitable cell
source which can diﬀerentiate into, and maintain, the speciﬁc
cell phenotype; research in this area forms the body of this
review (see Table 1). Additionally, signalling molecules such
as growth factors, cytokines, or hormones stimulate cell
growth and diﬀerentiation, and traditionally, a scaﬀold is
used to provide an adequate three-dimensional environment
[4, 5], although scaﬀold-free techniques have also proven
successful (reviewed in Shimomura et al. [6]).
Growth factors, cytokines, and hormones are used to
stimulate cell proliferation (owing to the low number of
endogenous progenitors) and induce chondrocytic diﬀerenti-
ation (without inducing hypertrophy or causing transforma-
tion) leading to the secretion of a collagen-rich extracellular
matrix (ECM). Growth factors exert their eﬀects by binding
to, and activating, speciﬁc membrane-bound (usually trans-
membrane) receptors. Ligand binding typically leads to the
activation of an intracellular signalling cascade (such as
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Table 1: Summary of recent results in the application of stem and progenitor cells to cartilage repair and regeneration.
(a)
Author Year
Cell
source
Model Experimental study
Adverse
eﬀects
Key ﬁndings
Shaﬁee et al. 2011 Cartilage Mice
Proliferation, tumourigenesis,
and multipotency of nasal
septum-derived adult cells
None
NCs retained chondrogenic potential
until passage 35. Markers suggest
chondrogenic ability equal to that of
BMSCs
do Amaral et al. 2012 Cartilage In vitro
Proliferation and multipotency of
nasal septal cartilage surface zone
cells within the context of cartilage
repair
NA
Cells in pellet culture resulted in
chondrogenesis without TGF-β or
BMPs. NCs were CD105+, CD73+,
CD44+, and CD146−
Pelttari et al. 2014 Cartilage
Humans (10),
mice, goats
Suitability of adult human
neuroectoderm-derived nasal
chondrocytes for articular
cartilage repair
None
NCs proliferated faster and were more
chondrogenic than Acs in vitro. In vivo,
defectﬁllingwas observed after 4months
Jiang et al. 2016 Cartilage
Humans (15),
mice
Cartilage repair potential
of resident cartilage
stem/progenitor cells
None
ACs became CD146+ in high-density
2D culture, and their chondrogenic
potential is similar to that of BMSCs. In
vivo results were promising
Embree et al. 2016 Cartilage Rats, rabbits
Potential of single resident
ﬁbrocartilage stem cells (FCSC) to
regenerate cartilage, bone, and
haematopoietic compartment
None
FCSCs spontaneously produced cartilage
anlage in vivo which was then remodeled
into trabecular bone. Addition of
sclerostin maintained the FCSC pool and
led to chondrocyte diﬀerentiation and
cartilage repair in vivo
Fellows et al. 2017 Cartilage In vitro
Senescence of healthy versus
diseased human knee articular
cartilage rather than regenerative
potential per se
NA
The number of progenitor cells was
greater (2x, P < 0 001) in OA tissue than
in healthy cartilage. Subpopulation of
OA-derived cells had reduced
proliferative potential and underwent
early senescence in vitro. An increase in
senescent cells may contribute to the
disease phenotype
Pittenger et al. 1999 BM In vitro
Maintenance of multipotency in
individual adult BMSCs
NA
Adult stem cells can be induced to
diﬀerentiate exclusively into adipocytic,
chondrocytic, and osteogenic lineages
Wakitani et al. 2004 BM Humans (2)
Eﬀectiveness of autologous BMSC
transplantation for the repair of
full-thickness articular cartilage
defects in the patellae of 2
individuals
None
Clinical symptoms (pain & walking
impediment) were signiﬁcantly reduced
6 months postop. Beneﬁts remained for
4-5 years. Arthroscopy revealed defects
ﬁlled with ﬁbrocartilage
Wakitani et al. 2011 BM Humans (41)
Safety of autologous BMSC
implantation for cartilage defects
None
No tumour or infections reported in any
patient. Five had total knee replacement
due to progression to OA
Wong et al. 2013 BM Humans (56)
Autologous BMSC i.a. injections
with microfracture and tibial
osteotomy
None
The experimental group showed
signiﬁcantly better IKDC (P = 0 001),
Tegner (P = 0 021), MOCART (P <
0 001), and Lysholm (P = 0 016) scores
(b)
Author Year Cell source Model What was examined Adverse eﬀects Key ﬁndings
Vangsness et al. 2014 BM
Humans
(55)
Safety and eﬀects on OA
changes in the knee following
intra-articular injection of
allogeneic human BMSCs
None
Evidence of meniscus
regeneration and improvement
in knee pain following
treatment with allogeneic
humanmesenchymal stemcells
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Table 1: Continued.
Author Year Cell source Model What was examined Adverse eﬀects Key ﬁndings
Gobbi et al. 2014 BM
Humans
(25)
BMAC (BM aspirate
concentrate) for the repair
of large full-thickness knee
cartilage defects
None
Signiﬁcant improvement in
Tegner, Marx, Lysholm, VAS,
IKDC subjective, and KOOS
scores at the ﬁnal follow-up
compared with their respective
preoperative scores (P < 0 001);
MRI analysis at the ﬁnal
follow-up showed stable
implantation and complete
ﬁlling of the defect in 20 of 25
patients
Vega et al. 2015 BM
Humans
(30)
Eﬀects of i.a. injection of
allogeneic BMSC versus
hyaluronic acid for the
treatment of knee OA
None
At 1-year follow-up, cartilage
formation in cell-treated
defects was signiﬁcantly
improved over control
(HA)-treated defects
Nakagawa et al. 2016 BM Rats
Lubricin expression and
chondrogenesis in BMSCs
using pellets & hanging-drop
cultures in vitro and in vivo
NS
The treatment group scored
signiﬁcantly higher than the
control group when assessed
histologically at 8 and 12 weeks
Chen et al. 2016 BM Rabbits
PTH-treated versus
untreated BMSCs embedded
in ﬁbrin glue for the repair of
induced articular cartilage
injury in rabbits
None
The ICRS score signiﬁcantly
increased (P < 0 05) in PTH-
treated versus non-PTH and
untreated groups. Signiﬁcantly
increased levels of type II
collagen and aggrecan mRNA
and protein in PTH versus
non-PTH groups (P < 0 05)
Shapiro et al. 2017 BM
Humans
(25)
BMAC for the treatment of
knee pain from bilateral
osteoarthritis
None
Knee pain decreased in all
groups, although no signiﬁcant
diﬀerence between BMAC and
saline groups (P > 0 9)
Koga et al. 2008 Synovium Rabbits
“Local adherent technique”
whereby an i.a. injection of
synovium stem/progenitor
cells adheres to the defect site
within 10 minutes
NA
Increased cell attachment
correlated with improved
cartilage repair at 24 weeks. It
was reported that 60% of
injected cells adhered at the site
Nakamura et al. 2012 Synovium Pigs
Adherence of synovium-
derived cells to cartilage
defects and eﬀects on
cartilage
None
The cartilage matrix detected
in all treated defects versus
none in the control group.
Wakitani and ICRS scores
were signiﬁcantly higher in
treatment groups (P < 0 05).
Higher chondrogenic potential
in synovial cells versus BM,
adipose, muscle, or
periosteum-derived cells
Sekiya et al. 2015 Synovium
Humans
(10)
“Local adherent technique”
using autologous synovium-
derived stem/progenitor cells
1 patient had ﬁbrillation of
repaired cartilage
Transplantation of synovial
cells was deemed eﬀective:
Lysholm and MRI-based
scores increased over
3 years + follow-up period
(both P = 0 005)
Mak et al. 2016 Synovium Mice
Chondrogenic potential of
synovium-derived sca-1-
positive stem/progenitor cells
injected into injured joint
NS
Intra-articular injection of
Sca-1+ GFP+ synovial cells
from C57BL6 or MRL/MpJ
“super-healer” mice to C57BL6
mice following cartilage injury
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Table 1: Continued.
Author Year Cell source Model What was examined Adverse eﬀects Key ﬁndings
led to similar levels of cartilage
repair. Treatment with cells
resulted in cartilage repair that
was signiﬁcantly greater than
that of untreated defects
Baboolal et al. 2016 Synovium Dogs
Role of HA on MSC
attachment to cartilage
NS
It was conﬁrmed that HA
inhibits MSC-cartilage
attachment
Diekman et al. 2010 Adipose In vitro
Diﬀerences in chondrogenic
potential of ADSC and
BMSC in diﬀerent culture
conditions
NA
ADSCs and BMSCs require
diﬀerent in vitro culture
conditions to achieve optimal
chondrogenic outcomes.
While both ADSC and BMSC
underwent chondrogenic
diﬀerentiation in all conditions
tested, BMSCs produced a
more matrix over a wider
range of conditions
Koh et al. 2013 Adipose
Humans
(18)
Outcome of i.a. injections of
autologous ADSCs for the
treatment of knee OA
One case of pain and
swelling
Signiﬁcant reduction in
WOMAC scores (P > 0 001)
relative to preop levels. The
Lysholm score increased from
40.1 points to 73.4 points
(P > 0 001), and the mean VAS
score decreased over the period
of the study from 4.8 to 2.0
(P > 0 005)
Jo et al. 2014 Adipose
Humans
(18)
Safety and eﬃcacy of i.a.
injections of autologous
ADSC for knee OA
None
Improvements were seen in the
high-dose group
(improvement in WOMAC &
VAS at 6 months). Signiﬁcant
decreases in cartilage defect
size paralleled by an increase in
cartilage volume at some defect
sites at 6 months
Koh et al. 2015 Adipose
Humans
(30)
Injection of ADSCs and
arthroscopic lavage for knee
OA
Slight knee pain, resolved
with medication
The technique appears to be
eﬀective in cartilage healing,
reducing pain, and improving
function
Koh et al. 2016 Adipose
Humans
(80)
ADSCs with ﬁbrin glue and
microfracture (MFX) versus
MFX alone in patients with
symptomatic knee cartilage
defects
NS
Both treatment groups saw
improvement in multiple
clinical outcomes; however, the
degree of improvement was
greater in patients who
received ADSC in addition to
MFX
Pers et al. 2017 Adipose
Humans
(18)
Intra-articular injections of
diﬀerent doses of ADSCs
Unstable angina pectoris
reported in 1 patient, 5
minor AEs reported by
four patients potentially
related to the procedure
All dose groups saw an overall
negative trend in WOMAC
(pain, stiﬀness, and function),
VAS, and SAS, although these
data were signiﬁcant only in
the low-dose group
Saw et al. 2013
Peripheral
blood
Humans
(50)
Postoperative i.a. injections
of hyaluronic acid with and
without PBSC
None
A nonsigniﬁcant (P = 0 8)
increase in the IKDC score for
the PBSC group at 24 months.
A signiﬁcant (P = 0 013)
increase in the MRI score in
the PBSC group at 18 months
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Table 1: Continued.
Author Year Cell source Model What was examined Adverse eﬀects Key ﬁndings
Fu et al. 2014
Peripheral
blood
Rabbits
Mobilised rabbit PBSCs
versus rabbit BMSCs for
in vivo chondrogenesis
None
PBSCs showed greater
chondrogenic potential than
BMSCs in vitro, although both
cell types performed equally
well in in vivo assays for
cartilage repair
Fu et al. 2014
Peripheral
blood
Humans
(1)
Injection of autologous
activated PBSCs + autologous
periosteum ﬂap in a chondral
lesion
None
Second-look arthroscopy
showed a smooth surface at 8
months postoperation. CT and
MRI evaluations showed a
signiﬁcant improvement
compared to preoperation
Saw et al. 2015
Peripheral
blood
Humans
(8)
Autologous PBSCs and HA
with concomitant medial
open-wedge high tibial
osteotomy
None
At 25-month follow-up,
arthroscopy and biopsy
revealed smooth, well-
integrated regenerated tissue
rich in type II collagen and
proteoglycan, with some type I
collagen present
Ha et al. 2015
Umbilical
cord
Minipigs
Ability of human UBSC cell
lines in HA hydrogel (versus
empty defects) to repair
osteochondral defects
None
Defects which received
cells +HA had more safranin-
O-positive staining, more
regenerated cartilage, and
better integration with the
surrounding tissue. The
IRCS score was better in cell
transplant defects than in
empty defects
Li et al. 2016
Umbilical
cord
In vitro
It was determined whether
coculture of human ACs
could increase chondrogenic
potential of human UBSCs
NA
Indirect coculture increased
expression of chondrogenic
markers. However, qPCR, WB,
and some 2D IHC data contain
inconsistencies
Gomez-Leduc
et al.
2016
Umbilical
cord
Mice
Chondrogenic potential of
human UCBSCs seeded on
type I/III collagen sponges
± chondrogenic factors
NS
UBSCs cultured in vitro with
TGF-β1 and BMP-2 were
implanted in nude mice. Cells
exposed to growth factors in an
in vitro phase produced a
cartilaginous matrix rich in
type II collagen. No scaﬀolds
progressed to calciﬁcation but
instead deposited type II
collagen-rich ECM
Park et al. 2017
Umbilical
cord
Humans
(1)
Transplanted human
UCBSCs in a 4% HA
hydrogel into a rabbit
trochlea defect
None
VAS, IKDC, & WOMAC
improved. At 1-year follow-up,
second-look arthroscopy and
biopsy showed smooth
safranin-O-positive hyaline-
cartilage with excellent
peripheral integration. MRI
showed defect ﬁlling, abundant
repair tissue, and good
integration with the
surrounding tissue
Park et al. 2017
Umbilical
cord
Humans
(7)
Treatment of a large
osteochondral defect by
autologous UCBSCs in a HA
hydrogel
None
Regenerated tissue was thick,
smooth, and glossy white with
good integration with the
surrounding tissue and
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MEK/ERK, protein kinase C, and PI3K/AKT) and/or tran-
scription factors, resulting in altered gene expression. Genes
related to proliferation and diﬀerentiation are common tar-
gets of ﬁbroblast growth factor 2 (FGF-2), which has been
utilized for BMSC expansion [7], while insulin-like growth
factor 1 has been applied to chondrogenic diﬀerentiation of
peripheral blood (PB) cells [8] and to the repair of cartilage
defects in rabbits [9]. Members of the TGF-β superfamily,
which include TGF-β1 and BMPs 2, 4, and 7, have been
shown to inﬂuence the development of cartilage [10] but
may skew diﬀerentiation towards hypertrophic chondrogen-
esis and endochondral ossiﬁcation [11], and TGF-β has been
linked to cancerous progression in humans [12]. Alterna-
tively, growth diﬀerentiation factor 5 has been shown to reg-
ulate the diﬀerentiation of articular chondrocytes [11] at least
in part through inhibition of the BMP4 pathway [13].
Methods for the isolation and preparation of stromal cell
populations are not standardized. Indeed, the method of iso-
lation and preparation and the degree of ex vivo manipula-
tion vary widely between laboratories and donor tissue
source. Generally, tissue samples are harvested in sterile con-
ditions, and cells are isolated with by diﬀerent methods
(enzymatic digestion or direct culture). Subsequently, cells
are cultured in vitro with diﬀerent conditions. The most pop-
ular method to induce chondrogenesis consists in of pellet
culture with conditioned medium, which is enriched with
insulin, dexamethasone, ascorbic acid, sodium pyruvate,
and growth factors, such as TGF-βs or BMPs [14]. Chondro-
genesis is then conﬁrmed by the analysis of the extracellular
matrix (production of GAGs) and by gene expression of
cartilaginous markers (i.e., collagen type II, Sox-9).
The choice of scaﬀold material is signiﬁcant as the 3D
microenvironment is important for the correct growth and
diﬀerentiation of cells [5, 15–18]. This microenvironment
includes not only the materials which constitute the scaﬀold
and their characteristics (such as porosity [19], rigidity [18],
and biodegradability [16]) but also the in vitro culture condi-
tions (media formulations, as well as both hydrostatic and
mechanical forces [20, 21] and oxygen levels [22] that cells
are exposed to).
Thus, growth factors and scaﬀolds are often combined
with cells for regenerative purposes. For cartilage repair, sev-
eral cell sources are already available and others are rapidly
emerging; the aim of this manuscript is to provide an over-
view of recent developments in the ﬁeld, with a particular
focus on stem cells.
2. Terminally Differentiated Cells or
Multipotent Cells for Cartilage Repair
Articular chondrocytes have been extensively used in the past
years for autologous chondrocyte transplantation. However,
the use of articular chondrocytes is limited by several factors:
morbidity at the harvest site, the requirement of a second
surgical procedure, and cell dediﬀerentiation due to in vitro
expansion [4, 23–25], necessitated by the limited number of
harvestable cells. Alternative sources of diﬀerentiated chon-
drocytes have been investigated, and recently, in a ﬁrst-in-
human trial, autologous nasal septum chondrocytes were
used for the repair of full-thickness articular cartilage defects
of the knee [26]. At 2-year follow-up, the changes in a range
of clinical scores (IKDC, KOOS pain, KOOS symptoms,
KOOS function in daily living, KOOS sport, and KOOS qual-
ity of life, relative to preintervention) were positive and the
safety of the procedure was conﬁrmed [26]. A phase II clini-
cal trial (NCT01605201) is currently underway to conﬁrm
these data.
Stem cells are a cell source of vast potential, which can be
isolated from a range of diﬀerent tissues. These cells consti-
tute a self-renewing population, which can undergo multili-
neage diﬀerentiation [27]. Pluripotent embryonic stem cells
derive from the fertilization of the egg, and they can diﬀeren-
tiate into any of the three germ layers (endoderm, mesoderm,
or ectoderm); thus, they possess the potential to diﬀerentiate
into any cell lineage. The role of these cells for tissue engi-
neering has been investigated since the late ‘90s; however,
along with induced pluripotent stem cells (iPSCs), the poten-
tial tumourigenicity and ethical issues have limited their use
in clinical practice (with the notable exception of umbilical
cord-derived stem cells [28, 29]). Conversely, adult postnatal
stem cells can be more easily utilized for tissue engineering.
These cells have a limited self-renewal and multilineage
potential [27, 30, 31], but they can be isolated from individ-
uals of any age without the ethical dilemmas of embryonic
stem cells. The term “mesenchymal stem cell’ (MSC) [32]
describes a speciﬁc subpopulation of adult stem cells on the
Table 1: Continued.
Author Year Cell source Model What was examined Adverse eﬀects Key ﬁndings
resembled hyaline-like
cartilage with abundant GAG
content. No bone formation or
overgrowth was observed
Park et al. 2017
Umbilical
cord
Rabbits
Eﬃcacy of human autologous
UCBSCs and HA hydrogels
for cartilage regeneration
None
Macroscopically, cells +
hydrogel produced better
cartilage formation than
hydrogel only or untreated
controls. Regenerated tissue
was smooth and type II
collagen rich
NA: not applicable; NS: not stated.
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basis of established “minimal criteria” identiﬁed by the Inter-
national Society for Cellular Therapy (ISCT) [33, 34] includ-
ing several cell-surface markers, adherence to plastic culture
dishes, and the potential to diﬀerentiate into chondrogenic,
osteogenic, myogenic, adipogenic, and tenogenic lineages.
Cell populations conforming to these criteria can be isolated
from several tissues: bone marrow, synovium, adipose tissue,
periosteum, peripheral blood, and umbilical cord blood, as
well as from the inner part of cartilage of the knee. It must,
however, be pointed out that often, these cell populations
which are labelled “stem cells” would be more accurately
described as stem cell-containing populations. Frequently,
the multipotency and self-renewal capacity of these cells are
not reported despite the existence of simple tests to do so,
such as the colony-forming assay (CFU). The number of
actual stem cells isolated from tissue can vary enormously
depending on the age of the patient, the technique used for
isolation, and the source tissue [31]. The omission of this data
makes it challenging to assess the true role of the stem cell as
opposed to stromal cells in these studies and to make mean-
ingful comparisons between diﬀerent studies [35]. Finally,
the term “MSC” is sometimes used with no additional infor-
mation as to the tissue of origin, while stromal cell popula-
tions isolated from the bone marrow or adipose tissue, for
example, may both conform to the ISCT criteria for “MSCs”;
they diﬀer at the epigenetic [36] and phenotypic levels [37,
38] making the inclusion of this information crucial.
The chondrogenic potential of numerous stem cells has
been analysed with regard to their possible use in tissue engi-
neering. Probably, the most obvious source of stem cells to
regenerate cartilage tissue is cartilage itself, and many studies
have sought to isolate and harness the regenerative power of
cartilage-resident stem/progenitor cells, some with great
success [39–41] (see Table 1). Early studies followed from
the illustration of the multilineage potential of BMSCs [27]
culminate at the end of the last century with the demonstra-
tion of the exclusive and stable diﬀerentiation of clonal
BMSC populations into chondrocytes [41]. Since then,
researchers have capitalised the diversity of tissues from
which stem/progenitor cells can be extracted.
Hereafter, we will singularly describe the diﬀerent tissue
sources of stem cells (Figure 1).
2.1. Cartilage. Tissue engineering strategies utilizing autolo-
gous cartilage-derived stem/progenitor cells have been
attempted since the late 1980s [42–45]. The largely acellular
character of cartilage [44] combined with the scarcity of pro-
genitors has been a hurdle to its use; however, some success
has been seen using the cells resident in the articular cartilage
of the knee [42, 45] and the jaw [39]. The advantage of chon-
drocytes and cartilage-resident cells is their ability to survive
in the hypoxic environment found in the wound/implant.
Successful results have also been reported using cells taken
from the nasal septum [26, 46–48].
The articular cartilage of the knee is a thin layer of largely
acellular connective tissue that protects and facilitates the
movement of the joints [44]. Due to the low number of resi-
dent progenitor cells and challenges in deﬁning the charac-
teristics of the cartilage stem/progenitor cell [1], cartilage
isolates have proven unconducive to in vitro cartilage pro-
duction and any in vitro manipulation must be checked for
unintended subsequent osteogenesis or tumourigenesis after
implantation.
Recently, resident cartilage progenitor cells isolated from
autologous cartilage tissue were shown to form tissue with
the characteristics of hyaline cartilage when implanted
ectopically in a mouse model; this was supported by data
from high-density 2D cultures [39]. These cells were
expanded in vitro and implanted in the knees of patients
on a collagen scaﬀold. Patients reported signiﬁcant improve-
ments (using both IKDC and Lysholm scoring systems);
importantly, MRI indicated that the implants covered the
defect site and that no sign of hypertrophy was present;
histological examination of a subset of implants showed no
calciﬁcation, inﬂammation, or vascularisation. In addition
to the improved clinical scores, 14 of 15 patients resumed
sports activities within 1 year of the intervention, indicative
of the practical value of this technique for improving patient
quality of life.
Another study overcame the paucity of resident ﬁbrocar-
tilage stem cells (FCSC) within the jaw articular cartilage
through prolonged in vitro culture [37]. Animal studies
showed that a single FCSC was capable of generating a carti-
lage template that was remodelled into bone and a bone mar-
row space, including the haematopoietic microenvironment,
without exogenous stimulation from osteogenic scaﬀolds
(such as hydroxyapatite), Matrigel or factors, such as BMPs.
This would seem to be great news for bone tissue engineers,
but not so great for cartilage regeneration as formation of
bone within the articulation is hardly an ideal outcome.
However, the authors describe the mechanism by which the
pool of resident FCSCs is maintained, though the inhibition
of WNT signalling by sclerostin. Indeed, application of scler-
ostin favoured the diﬀerentiation of FCSCs into mature
chondrocytes and aided cartilage repair in a rabbit model of
cartilage injury [37].
The potential of cells from the nasal septum cartilage for
tissue engineering applications was hinted at by basic studies
from 2011 to 2012 [46, 48]. Through in vitro experiments
and mouse studies, the inherent chondrogenic potential of
nasal chondrocytes (NCs) was shown to be similar to that
of matched BMSCs with NCs undergoing chondrogenesis
in pellet culture without stimulation from either TGF-β or
BMPs [46]. Signiﬁcantly, NCs retained their chondrogenic
abilities for far longer, until passage 35, in line with observa-
tions that NCs displayed lower levels of senescence markers
than BMSCs [48] which would indicate that NCs could be
advantageous for tissue engineering strategies that call for
multiple rounds of ex vivo expansion. Dediﬀerentiated NCs
have been shown to have greater clonogenic potential (over
3-fold more) and to proliferate faster that articular chondro-
cytes [38]. Unlike BMSCs, NCs were not susceptible to adi-
pogenic induction [46, 48], possibly due to the signiﬁcantly
higher levels of BMP2 mRNA in NCs [48]. In vivo, NCs dis-
played no tumourigenicity or signs of metastasis in mice after
4 months, and clinical data show that autologous ex vivo-
expanded NCs ﬁlled the defect and had no signs of delamina-
tion after a similar period of time [38].
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2.2. Bone Marrow. Substantial clinical information is avail-
able on the suitability of bone marrow stromal cells (BMSCs)
for cartilage tissue engineering. From initial results showing
the potential for cartilage repair [41] to multiple clinical tri-
als [45, 49–54], there is ample evidence to illustrate the
applicability of BMSCs to cartilage defect repair. The
majority of studies have focused on the use of autologous
cells [45, 49–51, 53, 54]; however, there are also instances
of successful application of allogeneic stem cell preparations
to cartilage repair [52].
Removal of the bone marrow is usually achieved by aspi-
ration from the iliac crest of the pelvis. While this is less inva-
sive than some other methods of harvesting cells, the number
of stem/progenitor cells obtained is not high and some form
of expansion is often performed to obtain suﬃcient cell
numbers. Aside from the concerns about the loss of cell mul-
tipotency during 2D cell culture [55], this remains the stan-
dard method for expansion of BM stromal cell samples. In
some cases, the 2D expanded cell population is then embed-
ded or seeded on a scaﬀold which provides rigidity and form,
before being implanted at the defect site: the choice of scaf-
fold material is not trivial and may inﬂuence the diﬀerentia-
tion of the embedded cells [56]. The eﬃcacy of 2D expansion
followed by implantation on a cartilage-based scaﬀold has
been demonstrated in the lab and in the clinic [45, 49, 51,
53, 54] with follow-up times up to 11 years [53]. Clinically
scaﬀold-based BMSC implantation resulted in signiﬁcant
improvements in various indicators of quality of life and joint
function, including increased mobility and reduction of pain.
Although not all patients are willing to undergo second-look
Bone
marrow
Peripheral
blood
Umbilical
cord
Cartilage
regeneration
Synovium Adipose
Figure 1: Stem cell sources for cartilage repair.
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arthroscopy to assess cartilage formation and coverage, some
data exists which shows that some defects were ﬁlled with
ﬁbrocartilage [49]. Scaﬀold-free administration of BMSCs
expanded in vitro to form a “cell sheet” has also been shown
to be eﬀective in an animal model of cartilage defects at 12
weeks [7]. Here, FGF-2, in combination with chondrogenic
factors, was noted to increase chondrogenic diﬀerentiation
as well as cell growth [7]. Intra-articular (i.a.) injection of
BMSCs alone [57, 60, 61] or with additional materials (such
as hyaluronic acid (HA)) [59] has been applied to cartilage
repair in clinical studies. The results were mostly positive,
with an improvement in articular cartilage and meniscal
repair noted in patients treated with BMSCs as opposed to
controls (when analysed by IKDC, Tegner, and Lysholm
scores, as well as MRI and MOCART scores in addition to
evaluations of pain and quality of life) [50, 54].
Owing to the low frequency of stem/progenitor cells
within the BM and the period of time required for in vitro
expansion (typically several weeks), an alternate approach
has been used for bone marrow aspirate concentrate
(BMAC) [49, 50]. This technique has produced mixed results
for the treatment of both osteoarthritis (OA) and cartilage
defects in the knee. Gobbi and colleagues describe a case
series with signiﬁcant improvements in multiple scoring
matrices (Tegner, Marx, Lysholm, VAS, IKDC subjective,
and KOOS scores: P > 0 001) at 41 months postoperation
(postop), relative to the same tests prior to the intervention
[49]. On the other hand, Shapiro et al., in a randomised con-
trolled trial for the treatment of bilateral OA, injected
patients with either saline or BMAC, with follow-up at 6
months only to ﬁnd that the level of pain relief aﬀorded
was similar in both treatment and control groups [50]. An
additional technique involves the in vitro use of FGF-2 to
rapidly expand autologous BMSCs to the point where it is
feasible to generate a scaﬀold-free osteochondral implant
thus partially overcoming the often limiting number of
BMSCs obtainable from patients [7].
Caution must be exercised when using cells derived from
the BM for cartilage repair, as the cells that generate hyaline
cartilage are distinct from the growth plate chondrocytes
found in the BM which form hypertrophic cartilage that is
then remodelled into bone [13, 57–60]. Also, there is evi-
dence suggesting that the diﬀerentiation and colony-
forming potential of BMSCs decrease with donor age, a
potential hurdle for autologous use in the elderly [61].
Future prospects for the use of BMSCs for cartilage engi-
neering include the application of 3D printing technologies
to tissue engineering with various groups reporting on the
fabrication of 3D scaﬀold materials [62–64]. Recently, the
concept has been taken to the next logical step, and a mixture
of viable BMSCs and various polymers was used to create a
3D ECM containing live cells which survived in vivo and
expressed markers of chondrocytic diﬀerentiation [62].
2.3. Synovium. It has been shown, via lineage tracing, that
articular chondrocytes derive from synovial joint progeni-
tors, or interzone cells [57], which do not contribute to the
growth plate and thus to the formation of bone though endo-
chondral ossiﬁcation. This represents an advantage in the
ﬁeld of cartilage tissue engineering as heterotopic ossiﬁcation
is to be avoided. The development of articular chondrocytes,
as opposed to hypertrophic chondrocytes, has been shown to
be inﬂuenced by the TGF-β pathway, as opposed to signal-
ling through BMP4 [13].
Synovial cells have been assessed for their use in cartilage
repair, although few clinical data are published. Basic studies
in animal models however are promising showing that
synovium-derived cells represent a valid option for continu-
ous study. Mak et al. found a population of synovial sca-1+
progenitor cells with inherent chondrogenic potential which
were shown to increase cartilage repair 4 weeks after i.a.
injection in a mouse model [65], while Baboolal and col-
leagues present results suggesting that HA present in the
synovial ﬂuid inhibits the initial interaction between stromal
cells and cartilage [66]. These last results may be signiﬁcant
as inhibition of early binding events could be deleterious
for the repairing potential of injected cells. Indeed, a series
of studies from researchers at Tokyo Medical and Dental
University in Japan have illustrated the signiﬁcance of early
cell attachment through the use of their “local adherent tech-
nique”whereby a short period (10 minutes) of joint immobil-
ity is suﬃcient for improved attachment of synovium-
derived stem cell populations and results in signiﬁcantly
improved healing in both nonhuman animals and clinical
studies [67–69].
2.4. Adipose Tissue. In 2001, Zuk et al. demonstrated that
adipose-derived stromal/stem cells (ADSCs) can be diﬀeren-
tiated into chondrocytes, adipocytes, and osteoblasts [70]
paving the way for a host of studies into the application of
autologous ADSCs in regenerative medicine [71–73]. As in
the neighbouring ﬁeld of bone regenerative medicine, where
proponents of BMSC-based or ADSC-based cell therapies
cite the merits of either tissue versus the other [40], the same
is true for cartilage engineering. There are parallels between
the ﬁelds, and the various merits are somewhat overlapping.
On the one hand, the accessibility and abundance of adipose
tissue are an obvious advantage over the limited volumes that
can be collected from the bone marrow, with less comorbid-
ity to boot. ADSCs were shown to have a higher clonogenic
potential and lower tendency towards osteogenic diﬀerentia-
tion [74]. On the other hand, the regenerative potential of
ADSCs versus BMSCs, millilitre for millilitre, appears to
favour the use of the less abundant, harder to access, BMSCs.
Indeed, in vitro comparisons of the chondrogenic potential of
human BMSCs and ADSCs have concluded that BMSCs pos-
sess a greater chondrogenic potential than matched ADSCs
[75, 76]. An important paper from 2010 highlighted the
potential pitfalls of comparing BMSC and ADSC for cartilage
regeneration using in vitro culture conditions that were opti-
mised to one cell type, at the expense of the other [71]. Nev-
ertheless, the same authors concluded that while both ADSCs
and BMSCs underwent chondrogenic diﬀerentiation, it was
the latter that produced the greater amount of matrix over
a greater range of culture conditions.
In recent years, a number of clinical studies have focused
on the chondrogenic potential of ADSCs [71, 74–77]. Jo et al.
compared various doses of autologous ADSCs administered
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via i.a. injection in both phase I and II trials and concluded
that better results positively correlated with higher numbers
of ADSCs [77]. The highest dose (100 million cells) produced
smooth glossy white cartilage that was well integrated with
the subchondral bone, comparable to native cartilage and
free of calciﬁcation at 6 months postinjection. Importantly,
in the highest dose, the defect underwent signiﬁcant reduc-
tion in volume paralleled by an increase in cartilage volume
in some cases at 6-month follow-up; lower doses of ADSCs
did not produce such positive results. In contrast to these
ﬁndings, a recent clinical trial (NCT01585857) reported that
the lowest dose (2 million cells) of autologous ADSCs
injected i.a. for knee OA produced the greatest improvement
in pain and function tests using the Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC),
although this seems to be primarily due to the diﬀerences
in baseline pain and function seen in the low-dose group
[78]. Indeed, little diﬀerence is seen at later time points [78].
Further positive results were reported using the autolo-
gous stromal vascular fraction (SVF) harvested from the
buttocks of 30 patients which were then reinjected intraoper-
atively to assess the clinical eﬀect on elderly patients with
knee OA [72]. Assessment at 2 years showed improvements
in motor function, cartilage healing, and reduced pain. After
2 years, the average Lysholm score increased (from 54 to 74),
the VAS pain score decreased (from 4.7 to 1.7), and the
KOOS increased in all categories at all postoperative time
points. The same group followed up the previous study with
a level II, prospective comparative study to compare the clin-
ical and radiologic eﬃcacy of ADSCs harvested from the
SVF, with ﬁbrin glue and microfractures (MFX) versus
MFX alone in 80 patients with knee cartilage defects [73].
The outcomes at 24 months suggest that the addition of
ADSCs to MFX protocols could signiﬁcantly reduce OA pain
(reﬂected in improved MOCART and KOOS scores). The
authors reported no signiﬁcant eﬀects of ADSCs on other
matrices measuring daily activity and quality of life.
2.5. Peripheral Blood.Cells isolated from the peripheral blood
and activated using a combination of the CXCR4 antagonist,
AMD3100, and granulocyte colony-stimulating factor have
been noted to conform to the criteria deﬁning “MSCs” [79,
80] as laid out by the ISCT. In vitro studies using rabbit
peripheral blood cells (PBSCs) have shown that not only
are these cells substantially more accessible than the corre-
sponding BM-derived cells but that they also possess a
greater chondrogenic and adipogenic diﬀerentiation poten-
tial in in vitro assays [79]. In the same in vitro tests, BMSCs
had a greater osteogenic and proliferative capacity while
implantation of both BMSCs and PBSCs produced similar
chondrogenic results in an in vivo cartilage defect model.
In humans, PBSCs have produced diﬀerent results when
applied to cartilage repair. In a trial comparing 5 weekly
injections of HA only or HA plus PBSCs after arthroscopic
subchondral drilling for chondral lesions, improvements
were noted at 24 months using the IKDC score (P = 0 8),
using MRI inspection (P = 0 013), and using the ICRS score
(109-point increase, P = 0 022) [81]. It would be interesting
to see further studies expanding an essential “cells versus
no cells” experiment to include the eﬀects of other stem cells,
such as ADSCs or BMSCs. An extension of the above study
by the same group repeated the i.a. injections of HA±PBSCs
weekly for 5 weeks and again at 6, 12, and 18 months after
arthroscopic subchondral drilling in addition to open-
wedge high tibial osteotomy [82]. Assessment of cartilage
repair was carried out by histology (ICRS II scoring system)
and by second-look arthroscopy indicating that the tech-
nique including PBSCs produced cartilage rich in proteogly-
cans and collagen which closely resembled native cartilage
with no adverse eﬀects reported.
2.6. Umbilical Cord/Umbilical Cord Blood.Another emerging
source of stem cells for tissue regeneration is the umbilical
cord; with speciﬁc regard to cartilage repair and regeneration,
several recent reports have highlighted the potential for these
cells in the clinic [83–85]. In a recent case report, autologous
umbilical cord blood cells (UBSCs) in a HA hydrogel were
implanted in 5mm diameter and 5mm deep drilled holes
in the lateral femoral condyle. Assessment was at 1 and 5.5
years and showed improvements in VAS (from 46 preop to
8 and 12 at 1 and 5.5 years postop, resp.), IKDC (63.22 preop
to 85.02 and 85.5 at 1 and 5 years postop), and WOMAC
scores (25 preop to 2 and 4 at 1 and 5 years postop) [86].
Encouragingly at 1 year, second-look arthroscopy revealed
no bone formation or bone exposure at the articular surface
which was covered with smooth ﬁrm hyaline cartilage. MRI
at 1 and 5.5 years showed that the defect was ﬁlled, that there
was smooth integration with the surrounding tissue, and that
the repair was maintained over time. In a larger cohort of
patients (n = 7) assessed at 1, 3, and 7 years postintervention,
human allogeneic UBSCs mixed with a HA hydrogel were
evaluated for cartilage repair in the femoral condyle [87].
Human UBSCs as with stem cells from other sources have
been used allogeneically on the basis of their reputed immu-
nomodulatory properties [84, 88]. Ha et al. used human
UBSCs in a hydrogel to examine the repair potential of
osteochondral defects in a minipig model and noted no
adverse eﬀects, no infection, and no rejection after 12 weeks
[83]. Additionally, the UBSC-treated defects, in contrast to
the untreated controls, contained GAG-rich cartilage with
better integration with the surrounding tissue; the defects
which received human UBSCs also did better on the ICRS
scoring system.
3. Conclusions
The issue of degenerated cartilage will remain a pressing
medical need as the world population ages. Tissue engineer-
ing represents a valid alternative to current techniques, which
can oﬀer temporary or partial relief, but is far from ideal. As
illustrated in this review, a wide variety of tissues have been
examined for their potential suitability for cartilage regener-
ation or replacement. Each tissue has diﬀerent advantages
in terms of invasiveness, cell yield, cell proliferation, and
chondrogenic potential. Thus, the choice of the best cell
source depends on several factors: the intrinsic chondrogeni-
city, the ease of harvest, and the available cell number. In
general terms, it seems that more accessible tissues such as
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adipose, blood, and umbilical cord tissues have the advantage
despite their noncartilage origins. An alternative approach
involves the use of allogeneic cells or implants made using
allogeneic cells which are subsequently decellularised to
overcome this blockade.
This would permit the use of allogeneic cells for cartilage
repair, but at the expense of the potentially anti-inﬂammatory
eﬀects of live MSCs [89]. Indeed, downregulation of inﬂam-
matory cytokines has been reported in cocultures of ADSCs
and osteoarthritic chondrocytes or synoviocytes [90]. More-
over, reductions in reported pain following injection of stro-
mal cell populations from BM [91] and adipose tissue [77, 92]
have been reported. Thus, live MSCs may have a central role
in pain reduction following a cartilage repair procedure.
Existing techniques, such as autologous or allogeneic
chondrocyte implantation, can be optimised by drawing
upon fresh insights from basic science and by continuing to
experiment with new cell populations. Excitement over basic
ﬁndings must as always be tempered with caution regarding
the safety of treating cells with growth factors and hormones
prior to implantation. A balance between guiding cells down
the desired lineage path and pushing them over the edge
towards malignant transformation is crucial; however, there
are few reported instances.
The issue of premature diﬀerentiation during 2D in vitro
expansion is especially salient when discussing explanted
articular chondrocytes, which seem to have limited capacity
in this regard. Advances in cell culture techniques such as
the application of hypoxic growth chambers, as well as 3D
perfusion culture utilizing bioreactors that recapitulate not
only the 3D in vivo environment but also both hydrostatic
and compressive loading [93] found in joints, will be vital
to compensate for the low number of progenitors found in
articular cartilage. Research into alternate sources of
cartilage-forming cells is developing, as illustrated by the
range of cell sources covered in this review. Nowadays, autol-
ogous mesenchymal cells can already be applied in the clini-
cal settings; in particular, BMSCs or ADSCs can be injected
i.a. in case of moderate osteoarthritis with the aim to reduce
inﬂammation and, therefore, pain. In case of focal cartilage
lesions, BMSCs can also be used in combination with collage-
nic membranes to repair the defect. However, the use of
MSCs in clinical practice is still limited due to all the issues
described above.
Clearly, current methods can generate cartilage in vivo
with a great promise for future clinical applications. We
report on more than 15 case studies or clinical trials in
humans with the majority describing positive ﬁndings and
no adverse eﬀects with follow-up times extending to
double-digit ﬁgures. This is enormously encouraging, and
as we continue to learn more about the nature of progenitor
and stem cell populations, we anticipate that improvements
in the production of regenerated cartilage will see increased
clinical translation and patient beneﬁt.
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